2018 Annual Data Report - PowerPoint Presentation

2018 Annual Data ReportVolume 2: End-Stage Renal Disease Chapter 1:Incidence, Prevalence, Patient Characteristics, and Treatment Modalities

2Vol 2 Table 1.1 Trends in annual number of ESRD incident cases, crude and standardized incidence rates of ESRD, and annual percentage change in the U.S. population, 1980-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized to the age-sex-race distribution of the 2011 US population. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable; yr, year.

3Vol 2 Figure 1.1 Trends in the (a) crude and standardized incidence rates of ESRD, and (b) the annual percentage change in the standardized incidence rate of ESRD in the U.S. population, 1980-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized to the age-sex-race distribution of the 2011 US population. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable. (a) Incidence rate per million/year

4Vol 2 Figure 1.1 Trends in the (a) crude and standardized incidence rates of ESRD, and (b) the annual percentage change in the standardized incidence rate of ESRD in the U.S. population, 1980-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized to the age-sex-race distribution of the 2011 US population. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable. (b) One-year percentage change in standardized incidence rate

52018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.2 Trends in the annual number of ESRD incident cases, by modality, in the U.S. population, 1980-2016 Data Source: Reference Table D.1 and special analyses, USRDS ESRD Database. Persons with “Uncertain Dialysis” were included in the “All ESRD” total, but are not represented separately. Abbreviation: ESRD, end-stage renal disease.

62018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Table 1.2 Crude and standardized incidence rates of ESRD and annual number of ESRD incident cases, overall and by modality and ESRD Network (ordered from highest to lowest standardized rate), in the U.S. population, 2016

72018 Annual Data Report Volume 2 ESRD, Chapter 1Figure 1.3 Map of the standardized incidence rate of ESRD, by Health Service Area, in the U.S. population, 2012-2016 Data Source: Special analyses, USRDS ESRD Database. Standardized to the age-sex-race distribution of the 2011 US population. Special analyses exclude unknown age, sex, HAS and unknown/other race. Values for cells with 10 or fewer patients are suppressed. Abbreviation: ESRD, end-stage renal disease.

82018 Annual Data Report Volume 2 ESRD, Chapter 1vol 2 Figure 1.4 Trends in standardized ESRD incidence rate, by age group, in the U.S. population, 2000-2016 Data Source: Special analyses, USRDS ESRD Database. Standardized to the -sex-race distribution of the 2011 US population. Special analyses exclude unknown age, sex, and unknown/other race. Abbreviation: ESRD, end-stage renal disease.

92018 Annual Data Report Volume 2 ESRD, Chapter 1vol 2 Figure 1.5 Trends in standardized ESRD incidence rate, by race, in the U.S. population, 2000-2016 Data Source: Special analyses, USRDS ESRD Database. Standardized to the age-sex distribution of the 2011 US population. Special analyses exclude unknown age, sex, and unknown/other race. Abbreviations; AI/AN: American Indian/Alaska Native; NH/PI : ESRD , end-stage renal disease.

102018 Annual Data Report Volume 2 ESRD, Chapter 1vol 2 Figure 1.6 Trends in standardized ESRD incidence rate, by Hispanic ethnicity, in the U.S. population, 2000-2016 Data Source: Special analyses, USRDS ESRD Database. Standardized to the age-sex-race distribution of the 2011 US population. Special analyses exclude unknown age, sex, and unknown/other race. Abbreviation: ESRD, end-stage renal disease.

112018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.7 Cumulative incidence (%) of ESRD from birth to age 100+, by race/ethnicity, in the U.S. (a) male and (b) female populations, 2013 Source: Albertus et al. (Am J Kidney Dis, 2016). Abbreviation: ESRD, end-stage renal disease. **lifetime corresponds to follow-up of more than 100 years .   (a) Male Population

122018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.7 Cumulative incidence (%) of ESRD from birth to age 100+, by race/ethnicity, in the U.S. (a) male and (b) female populations, 2013 Source: Albertus et al. (Am J Kidney Dis, 2016). Abbreviation: ESRD, end-stage renal disease. **lifetime corresponds to follow-up of more than 100 years . (b) Female Population

132018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Table 1.3 Cumulative incidence (%) of ESRD from baseline age to follow-up age in the U.S. (a) male and (b) female populations, 2013   Duration of Follow-up Baseline age 10 Years 20 Years 30 Years 40 Years 50 Years 60 Years 70 Years 80 Years 90 Years 100 Years Lifetime** Birth 0.01 0.03 0.09 0.25 0.58 1.16 2.05 3.14 3.86 3.96 3.96 (0.01-0.01) (0.03-0.03) (0.09-0.10) (0.24-0.25)  (0.57-0.59) (1.15-1.17) (2.03-2.06) (3.12-3.17) (3.83-3.89) (3.93-3.99) (3.93-3.99) 10 Years 0.02 0.08 0.24 0.58 1.16 2.05 3.16 3.88 3.98 3.98 (0.02-0.02) (0.08-0.09) (0.23-0.24) (0.57-0.59) (1.15-1.17) (2.03-2.07) (3.13-3.18) (3.85-3.91) (3.95-4.01) (3.95-4.02 ) 20 Years 0.06 0.22 0.56 1.152.043.153.883.983.98(0.06-0.07)(0.21-0.23)(0.55-0.57)(1.13-1.16)(2.02-2.06)(3.13-3.18)(3.85-3.91)(3.95-4.01)(3.95-4.01)30 Years0.160.501.102.013.133.873.973.97(0.15-0.16)(0.50-0.51)(1.08-1.11)(1.99-2.02)(3.11-3.16)(3.84-3.90)(3.94-4.00)(3.94-4.00)40 Years0.350.961.883.033.783.883.88(0.34-0.36)(0.94-0.97)(1.86-1.90)(3.00-3.05)(3.75-3.81)(3.85-3.91)(3.85-3.91)50 Years0.631.582.773.553.653.65(0.62-0.63)(1.57-1.60)(2.74-2.80)(3.51-3.58)(3.62-3.69)(3.62-3.69)60 Years1.042.323.163.283.28(1.02-1.05)(2.30-2.35)(3.13-3.20)(3.24-3.31)(3.25-3.31)70 Years1.512.492.632.63(1.49-1.53)(2.46-2.53)(2.60-2.66)(2.60-2.67)80 Years1.421.61 1.61(1.39-1.45)(1.58-1.64)(1.58-1.65)90 Years0.510.52(0.48-0.54)(0.49-0.55)100 Years0.07(0.02-0.17) Source: Albertus et al. (Am J Kidney Dis, 2016). Abbreviation: ESRD, end-stage renal disease. **Lifetime corresponds to follow-up of more than 100 years.

142018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Table 1.3 Cumulative incidence (%) of ESRD from baseline age to follow-up age in the U.S. (a) male and (b) female populations, 2013 Source: Albertus et al. (Am J Kidney Dis, 2016). Abbreviation: ESRD, end-stage renal disease. **Lifetime corresponds to follow-up of more than 100 years.   Duration of Follow-up Baseline age 10 Years 20 Years 30 Years 40 Years 50 Years 60 Years 70 Years 80 Years 90 Years 100 Years Lifetime**   Birth 0.01 0.02 0.08 0.19 0.40 0.78 1.45 2.29 2.78 2.84 2.84   (0.01-0.01) (0.02-0.02) (0.08-0.08) (0.19-0.20) (0.39-0.41) (0.77-0.79) (1.43-1.46) (2.26-2.31) (2.76-2.81) (2.81-2.87) (2.81-2.87)   10 Years 0.02 0.07 0.19 0.39 0.78 1.45 2.29 2.79 2.85 2.85   (0.02-0.02) (0.07-0.08) (0.18-0.19) (0.39-0.40) (0.77-0.79) (1.43-1.47) (2.27-2.32)(2.77-2.82)(2.83-2.88)(2.83-2.88) 20 Years0.060.170.380.771.442.282.782.842.84 (0.05-0.06)(0.16-0.17)(0.37-0.39)(0.75-0.78)(1.42-1.45)(2.26-2.30)(2.76-2.81)(2.81-2.87)(2.82-2.87) 30 Years0.110.320.711.392.242.742.802.80 (0.11-0.12)(0.32-0.33)(0.70-0.72)(1.37-1.40)(2.22-2.26)(2.72-2.77)(2.77-2.83)(2.77-2.83) 40 Years0.210.611.292.152.652.712.71 (0.21-0.22)(0.60-0.62)(1.27-1.30)(2.13-2.17)(2.63-2.68)(2.69-2.74)(2.69-2.74) 50 Years0.401.101.982.502.562.56 (0.40-0.41)(1.09-1.11)(1.96-2.00)(2.47-2.52)(2.53-2.58)(2.53-2.58) 60 Years0.731.652.202.262.26 (0.72-0.74)(1.63-1.67)(2.17-2.22)(2.23-2.29)(2.24-2.29) 70 Years1.021.621.691.69 (1.00-1.04)(1.60-1.65)(1.67-1.72)(1.67-1.72) 80 Years0.780.870.87 (0.76-0.79)(0.85-0.89)(0.85-0.89) 90 Years0.190.20 (0.18-0.21)(0.18-0.21) 100 Years 0.02   (0.01-0.05)  

152018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Table 1.4 Trends in annual number of ESRD prevalent cases, crude and standardized ESRD prevalence, and annual percentage changes, in the U.S. population, 1980-2016   Prevalent count Crude prevalence Standardized prevalence   Year No. of cases % Change from previous year Prevalence (per million year) % Change from previous year Prevalence (per million year) % Change from previous year 1980 56,435 n/a   59.2 n/a   65.3 n/a 1981 64,258 13.9   74.6 26.0   83.1 27.3 1982 72,499 12.8   90.6 21.4   101.3 21.9 1983 85,581 18.0   109.4 20.8   123.1 21.5 1984 95,897 12.1   131.8 20.5   148.9 21.0 1985 105,4329.9 157.419.4 178.619.91986116,11910.1 190.521.0 217.021.51987127,4769.8 226.619.0 259.719.71988143,52612.6 284.125.4 329.626.91989162,70813.4 349.423.0 407.023.51990180,52611.0 395.913.3 461.713.41991199,55410.5 442.811.8 515.811.71992220,34510.4 500.012.9 581.212.71993240,5529.2 549.39.9 637.79.71994262,6279.2 607.210.5 704.210.41995281,5647.2 729.320.1 847.620.41996304,4208.1 865.118.6 1004.318.51997326,2187.2 979.113.2 1132.012.71998348,7616.9 1080.610.4 1244.19.91999369,6256.0 1166.37.9 1333.87.22000 390,566 5.7   1243.6 6.6   1410.65.82001 410,507 5.1   1311.1 5.4 1474.24.52002429,8874.7 1372.74.7 1526.83.62003448,5434.3 1427.94.0 1571.32.92004467,0884.1 1480.03.6 1610.22.52005485,9844.0 1531.13.5 1647.32.32006506,7644.3 1585.63.6 1686.82.42007526,8994.0 1637.33.3 1721.52.12008548,0194.0 1690.73.3 1756.42.02009570,7904.2 1749.03.4 1794.12.12010593,1723.9 1805.73.2 1829.01.92011613,0503.4 1855.12.7 1855.11.42012634,7283.5 1908.52.9 1884.11.62013657,9473.7 1965.23.0 1916.71.72014681,7833.6 2021.72.9 1948.21.62015705,4923.5 2077.12.7 1979.11.62016726,3313.0 2120.52.1 1998.31.0 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized to the age-sex-race distribution of the 2011 US population. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable.

162018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.8 Trends in the (a) crude and standardized prevalence of ESRD, and (b) annual percentage change in the standardized prevalence of ESRD, in the U.S. population, 1980-2016 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized for age, sex, and race. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable. (a) Prevalence per million

172018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.8 Trends in the (a) crude and standardized prevalence of ESRD, and (b) annual percentage change in the standardized prevalence of ESRD, in the U.S. population, 1980-2016 Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude U.S. territories, unknown age, and unknown/other races. Standardized for age, sex, and race. Abbreviations: ESRD, end-stage renal disease; n/a, not applicable. (b) One-year percentage change in standardized prevalence

182018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.9 Trends in the number of ESRD prevalent cases, by modality, in the U.S. population,1980-2016 Data Source: Reference Table D1 and special analyses, USRDS ESRD Database. Abbreviation: ESRD, end-stage renal disease. Persons with “Uncertain Dialysis” were included in the “All ESRD” total, but are not represented separately.

192018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Table 1.5 Crude and standardized* prevalence of ESRD (per million) and annual number of ESRD prevalent cases, overall and by modality (hemodialysis, peritoneal dialysis, and transplantation) and ESRD Network (ordered from highest to lowest standardized rate), in the U.S. population, 2016     Total ESRD Hemodialysis Peritoneal dialysis Transplant Network States in network* No. of cases** Crude prevalence (per million) Standardized prevalence (per million) No. of cases % of network No. of cases % of network No. of cases % of network 3 NJ, PR, VI 28,864 3,141 2,870 13,398 63.7 1,005 4.8 6,572 31.2 18 S. CA 60,362 2,446 2,618 40,597 67.3 4,737 7.8 14,895 24.7 14 TX 65,415 2,321 2,490 45,145 69.0 4,237 6.5 15,837 24.2 10 IL 31,906 2,473 2,293 19,367 60.7 2,2747.110,17631.917N. CA, HI, GU, AS, MP39,8812,4172,27023,72661.23,3498.611,54129.811MI, MN, ND, SD, WI46,5732,0252,09425,86955.62,6825.817,86038.49IN, KY, OH48,3662,1202,06030,45863.03,7477.713,96528.912IA, KS, MO, NE26,2821,8602,02514,55355.42,2418.59,40335.84DE, PA30,5042,2122,01018,52960.71,9296.39,94632.613AR, LA, OK26,8512,3001,98118,07867.32,2898.56,35923.72NY45,3342,2581,96629,57665.21,6553.714,00830.98AL, MS, TN37,4462,5681,94825,36867.73,0638.28,90823.815AZ, CO, NV, NM, UT,WY37,4161,7461,87721,89258.52,8007.512,62333.7 5MD, DC, VA, WV 41,439 2,430 1,867 26,224 63.3 2,5916.312,48530.1 6 NC, SC, GA 64,220 2,501 1,81443,85968.35,3348.314,84923.17FL43,9882,1021,73828,31464.43,1707.212,33728.116AK, ID, MT, OR, WA23,0811,5321,69412,55554.41,9988.78,44236.61CT, MA, ME, NH, RI, VT24,5831,6531,64013,37954.41,4515.99,64839.2All network726,3312,2742,138450,88763.250,5527.1209,85429.4Data Source: Reference Table B.10 and Special analyses, USRDS ESRD Database. *Standardized to the age-sex-race distribution of the 2011 US population. Listed from highest to lowest standardized rate per million/year. The special analyses exclude U.S. territories, unknown age, sex, network, and unknown/other races. **No. of cases does include 50 states, Washington, D.C. (DC), Puerto Rico (PR), Guam (GU), American Samoa (AS), U.S. Virgin Islands (VI), and the Northern Mariana Islands (MP). Northern and Southern California (CA) split into Networks 17 and 18. Abbreviations: Af Am, African American; ESRD, end-stage renal disease; Hisp, Hispanic; N Am, Native American.

202018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.10 Map of the standardized prevalence of ESRD, by Health Service Area, in the U.S. population, 2012-2016* Data Source: Special analyses, USRDS ESRD Database. Standardized to the age-sex-race distribution of the 2011 US population. Special analyses exclude unknown age, sex, HSA and unknown/other race. *Four Health Service Areas were suppressed because the ratio of crude rate to standardized rate or standardized rate to crude rate was greater than 3. Values for cells with 10 or fewer patients are suppressed. Abbreviation: ESRD, end-stage renal disease.

212018 Annual Data Report Volume 2 ESRD, Chapter 1Vol 2 Figure 1.11 Trends in the standardized prevalence of ESRD, by age group, in the U.S. population, 2000-2016 Data Source: Special analyses, USRDS ESRD Database. Point prevalence on December 31 of each year. Standardized to the sex-race distribution of the 2011 US population . Special analyses exclude unknown age, sex, and unknown/other race. Abbreviations: ESRD, end-stage renal disease.

22Vol 2 Figure 1.12 Trends in the standardized prevalence of ESRD, by race, in the U.S. population, 2000-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Point prevalence on December 31 of each year. Standardized to the age-sex distribution of the 2011 US population . Special analyses exclude unknown age, sex, and unknown/other race. Abbreviations NH/PI: Native Hawaiian/Pacific Islander; AI/AN: Americans Indian/Alaska Natives; ESRD, end-stage renal disease.

23Vol 2 Figure 1.13 Trends in the standardized prevalence of ESRD, by Hispanic ethnicity, in the U.S. population, 2000-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Point prevalence on December 31 of each year. Standardized to the age-sex-race distribution of the 2011 US population. Special analyses exclude unknown age, sex, and unknown/other race. Abbreviation: ESRD, end-stage renal disease.

24Vol 2 Figure 1.14 Trends in the number of incident ESRD cases using home dialysis, by type of therapy, in the U.S. population, 1996-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Reference Table D.1 and special analyses, USRDS ESRD Database. Abbreviations: ESRD, end-stage renal disease.

25Vol 2 Table 1.6 Number and percentage of incident ESRD patients receiving hemodialysis (HD), peritoneal dialysis (PD), and a transplant, by age, sex, race, ethnicity, and primary cause of ESRD, in the U.S. population, 2016 2018 Annual Data Report Volume 2 ESRD, Chapter 1

26Vol 2 Figure 1.15 Map of the percentage of incident dialysis cases using home dialysis (peritoneal dialysis or home hemodialysis), by Health Service Area, 2012-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Values for cells with 10 or fewer patients are suppressed. Abbreviation: ESRD, end-stage renal disease.

27Vol 2 Figure 1.16 Trends in number of prevalent ESRD cases using home dialysis, by type of therapy, in the United States, 1996-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Reference Table D.1. December 31 prevalent ESRD patients. Peritoneal dialysis consists of continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal dialysis (CCPD), and intermittent peritoneal dialysis (other PD) only. Abbreviation: ESRD, end-stage renal disease.

28Vol 2 Table 1.7 Number and percentage of prevalent ESRD patients receiving hemodialysis, peritoneal dialysis, and a transplant, by age, sex, race, ethnicity, and the primary cause of ESRD, in the United States, 2016 2018 Annual Data Report Volume 2 ESRD, Chapter 1

29Vol 2 Figure 1.17 Map of the percentage of prevalent dialysis cases using home dialysis, by Health Service Area, 2012-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Values for cells with 10 or fewer patients are suppressed.

302018 Annual Data Report Volume 2 ESRD, Chapter 1Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. *Count ≤10. eGFR calculated using the CKD-EPI equation (CKD-EPI eGFR (ml/min/1.73 m2 ) for those aged ≥18 years and the Schwartz equation for those aged <18 years. Abbreviations: AV, arteriovenous; CKD-EPI, chronic kidney disease epidemiology calculation; CV, central venous; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agents; ESRD, end-stage renal disease; RRT, renal replacement therapy. vol 2 Table 1.8.a Distribution (in %) of the reported duration of pre- ESRD nephrology care, by category of each demographic variable, among incident ESRD cases in the U.S. population, 2016 (a) Demographic characteristics (% within row)

312018 Annual Data Report Volume 2 ESRD, Chapter 1vol 2 Table 1.8.b Distribution (in %) of clinical characteristics, by reported duration of pre-ESRD nephrology care, among incident ESRD cases in the U.S. population, 2016 Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. *Count ≤10. eGFR calculated using the CKD-EPI equation (CKD-EPI eGFR (ml/min/1.73 m 2 ) for those aged ≥18 years and the Schwartz equation for those aged <18 years. Abbreviations: AV, arteriovenous; CKD-EPI, chronic kidney disease epidemiology calculation; CV, central venous; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agents; ESRD, end-stage renal disease; RRT, renal replacement therapy. (b) Clinical characteristics (% within row)

32Vol 2 Figure 1.18 Map of the percentage of incident cases who had received >12 months of pre-ESRD nephrology care, by Health Service Area, 2012-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. Values for cells with 10 or fewer patients are suppressed. Abbreviations: ESRD, end-stage renal disease; Neph, nephrology.

33vol 2 Figure 1.19 Trends in the distribution of eGFR (ml/min/1.73 m2) among incident ESRD patients, 1996-2016 2018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. eGFR calculated using the CKD-EPI equation (CKD-EPI eGFR (ml/min/1.73 m 2 ) for those aged ≥18 and the Schwartz equation for those aged <18. Abbreviations: CKD-EPI; chronic kidney disease epidemiology calculation; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.

34vol 2 Table 1.9 Distributions of laboratory values (mean) and treatment characteristics (%), by age, sex, race, ethnicity, and the primary cause of ESRD, among incident ESRD cases, 20162018 Annual Data Report Volume 2 ESRD, Chapter 1

35vol 2 Figure 1.20 Map of mean eGFR at initiation of renal replacement therapy, by Health Service Area, 2012-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. eGFR calculated using the CKD-EPI equation (CKD-EPI eGFR (ml/min/1.73 m 2 ) for those aged ≥18 and the Schwartz equation for those aged <18. Values for cells with 10 or fewer patients are suppressed. Abbreviations: eGFR, estimated glomerular filtration rate; CKD-EPI, chronic kidney disease epidemiology calculation.

36vol 2 Figure 1.21 Map of mean hemoglobin level at initiation of renal replacement therapy, by Health Service Area, 2012-20162018 Annual Data Report Volume 2 ESRD, Chapter 1 Data Source: Special analyses, USRDS ESRD Database. Population only includes incident cases with CMS form 2728. Values for cells with 10 or fewer patients are suppressed. Abbreviation: ESRD, end-stage renal disease.

37vol 2 Table 1.10 Distribution of duration of pre-ESRD nephrology care (in %), mean hemoglobin level, and mean eGFR, by ESRD Network, among incident ESRD cases in the U.S., 2016 2018 Annual Data Report Volume 2 ESRD, Chapter 1